ANTIEMETIC CONTROL - 5-HT-3 ANTAGONISTS - REVIEW OF CLINICAL-RESULTS, WITH PARTICULAR EMPHASIS ON ONDANSETRON

被引：9

作者：

KIDGELL, AE

BUTCHER, ME

BROWN, GW

机构：

[1] Clinical Research (Infection and Oncology) Glaxo Group Research Ltd., Greenford, Middlesex

来源：

CANCER TREATMENT REVIEWS | 1990年 / 17卷 / 2-3期

关键词：

D O I：

10.1016/0305-7372(90)90063-L

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：311 / 317

页数：7

共 19 条

[1]

BONNETERRE J, 1989, P AM SOC CLIN ONCOL, V8, P324

[2]

CLAVEL M, 1989, 3RD FRENCH ASS THER

[3]

COSTALL B, 1987, BRIT J PHARMACOL, V56, P90

[4] PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST [J].

CUNNINGHAM, D ;

POPLE, A ;

FORD, HT ;

HAWTHORN, J ;

GAZET, JC ;

CHALLONER, T ;

COOMBES, RC .

LANCET, 1987, 1 (8548) :1461-1463

[5]

DELTANN LD, 1983, EUROPEAN J CANCER CL, V24, P1383

[6]

DICATO MA, 1989, 5TH OND SAT S EUR C

[7]

GREEN JA, 1987, BRIT J CANCER, V56, P899

[8]

LEIBUNDGUT U, 1987, LANCET, V1, P1198

[9]

LUCRAFT HH, 1987, ANN M ROYAL COLLEGE

[10]

MARSCHNER N, 1989, 5TH OND SAT S EUR C

← 1 2 →